Sangamo Can Take Lead In Fabry Gene Therapy

Gearing Up For Phase III

 
• By Andrew McConaghie
Sangamo
The Fabry disease gene therapy is one of three candidates Sangamo has in its wholly-owned pipeline • Source: Alamy

More from Rare Diseases

More from Scrip